In patients with chronic lymphocytic leukemia, large amounts of white blood cells (>50
In patients with chronic lymphocytic leukemia, large amounts of white blood cells (>50.0103cells/L) are a risk factor for rituximab-induced infusion reactions [12,13]. literature review revealed that rituximab administered during the second course of chemotherapy (instead of during the first course) appears to reduce the incidence of infusion reactions (from 48% to 15%) without altering the…
Read more